Loading…
Cerus Corporation is projected to rise to $4.10 by 2027, a +31% move from its current price of $3.12. CERS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $3.03 | $3.12 | $3.21 | 0.00% |
| Jul 13 | $3.00 | $3.12 | $3.25 | +0.01% |
| Jul 14 | $2.97 | $3.12 | $3.28 | +0.01% |
| Jul 15 | $2.95 | $3.12 | $3.30 | +0.02% |
| Jul 16 | $2.93 | $3.12 | $3.32 | +0.02% |
| Jul 17 | $2.91 | $3.12 | $3.34 | +0.03% |
| Jul 18 | $2.90 | $3.12 | $3.36 | +0.03% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.90 | $3.12 | $3.36 | +0.03% |
| Week 2 | $2.81 | $3.12 | $3.47 | +0.06% |
| Week 3 | $2.74 | $3.12 | $3.55 | +0.09% |
| Week 4 | $2.69 | $3.12 | $3.63 | +0.12% |
| Week 5 | $2.64 | $3.12 | $3.69 | +0.15% |
| Week 6 | $2.60 | $3.13 | $3.75 | +0.18% |
| Week 7 | $2.57 | $3.13 | $3.81 | +0.21% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cerus Corporation operates as a biomedical products company focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells intended for transfusion; INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced; and INTERCEPT Illuminator, an LED-based device for blood component treatment.
It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was formerly known as CERUS TECHNOLOGIES INC and changed its name to Cerus Corporation in July 1996. The company was incorporated in 1991 and is headquartered in Concord, California.
Cerus Corporation (CERS) is a healthcare company focused on blood safety through INTERCEPT Blood System products. It currently trades at $3.16 per share, with a market cap of $633.17M, and it ranks 2803. The stock shows bullish technical signals, with RSI14 at 70, and it trades above its 50-day moving average of $2.59 and above its 200-day moving average of $2.08.
The current price faces resistance at $3.16 and has support at $2.47. The 30-day price range spans $2.57 to $3.88, reflecting near-term dynamics and potential upside.
A major floor 45.8% below — a decisive break under it would weaken the trend.
The nearest floor, 20.8% below — buyers have tended to step in here.
The nearest ceiling, 5.1% above — a clean break opens room to run.
A major ceiling 20.7% above — clearing it would confirm fresh momentum.
Key CERS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CERS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.18 | Sell | $3.13 | Sell |
| MA 10 | $3.09 | Buy | $3.06 | Buy |
| MA 20 | $2.85 | Buy | $2.94 | Buy |
| MA 50 | $2.71 | Buy | $2.70 | Buy |
| MA 100 | $2.36 | Buy | $2.47 | Buy |
| MA 200 | $2.13 | Buy | $2.21 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 62.57 | Neutral |
| Stoch RSI (14) | 56.13 | Neutral |
| CCI (20) | 74.69 | Neutral |
| Williams %R (14) | -23.19 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | 20.46 | Buy |
| Bollinger %B (20,2) | 0.76 | Neutral |
| Stochastic %K (14) | 76.81 | Neutral |
| TRIX (15) | 0.65 | Buy |
| Awesome (5,34) | 0.38 | Buy |
| Ultimate (7,14,28) | 66.19 | Neutral |
| Momentum (10) | 0.26 | Buy |
| Aroon Osc (25) | 48.00 | Buy |
| Hull MA (9) | 3.19 | Sell |
| ADX (14) | 22.57 | Buy |
| ATR (14) | 0.08 | Info |
The near-term technical picture is bullish, with the RSI at 70 indicating strong momentum. The stock trades above the 50-day moving average of $2.59 and the 200-day moving average of $2.08, suggesting positive trend direction. Price action shows a near-term range from $2.57 up to $3.88 over the last 30 days, with resistance at $3.16 and support at $2.47.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.69 | $3.12 | $3.99 | 0% | Neutral | |
| $3.25 | $4.10 | $5.48 | +31% | Bullish | |
| $3.96 | $5.14 | $7.12 | +65% | Bullish | |
| $4.29 | $5.71 | $8.15 | +83% | Bullish | |
| $4.71 | $6.40 | $9.37 | +105% | Bullish | |
| $4.61 | $6.39 | $9.56 | +105% | Bullish | |
| $4.88 | $6.88 | $10.50 | +120% | Bullish | |
| $5.94 | $8.51 | $13.22 | +173% | Bullish | |
| $6.90 | $10.05 | $15.88 | +222% | Bullish | |
| $7.40 | $10.94 | $17.54 | +251% | Bullish | |
| $10.80 | $17.13 | $29.26 | +449% | Bullish | |
| $15.80 | $28.29 | $52.98 | +807% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.69 | $3.12 | $3.79 | +0.00% |
| August 2026 | $2.64 | $3.12 | $3.79 | +0.15% |
| September 2026 | $2.63 | $3.13 | $3.85 | +0.24% |
| October 2026 | $2.72 | $3.26 | $4.04 | +4.12% |
| November 2026 | $2.72 | $3.27 | $4.09 | +0.32% |
| December 2026 | $2.62 | $3.17 | $3.99 | -3.10% |
Click any year to see its month-by-month CERS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect CERS to range from $1.69 to $3.99 through 2026. The $3.12 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The CERS price prediction for 2027 points to an average of $4.10 (low $3.25, high $5.48) — a potential gain of +31% on today's $3.12. Buyers look set to stay in control over this stretch.
In 2028, CERS is projected to trade between $3.96 and $7.12, averaging $5.14 — a potential gain of +65% from today's $3.12. That is up +25% on the projected 2027 average. Momentum favours further upside here.
Cerus Corporation's 2029 outlook centres on $5.71, within a $4.29 to $8.15 range. That is up +11% on the projected 2028 average. That marks a +83% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, CERS could reach as high as $9.37, with a base case around $6.40 and support toward $4.71 — roughly +105% from $3.12. Momentum favours further upside here.
Expect CERS to range from $4.61 to $9.56 through 2031. The $6.39 average target implies a +105% move from current prices. That is 0% versus the projected 2030 average. Buyers look set to stay in control over this stretch.
The CERS price prediction for 2032 points to an average of $6.88 (low $4.88, high $10.50) — a potential gain of +120% on today's $3.12. Momentum favours further upside here.
In 2033, CERS is projected to trade between $5.94 and $13.22, averaging $8.51 — a potential gain of +173% from today's $3.12. That is up +24% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Cerus Corporation's 2034 outlook centres on $10.05, within a $6.90 to $15.88 range. That is up +18% on the projected 2033 average. That marks a +222% change versus current levels. Momentum favours further upside here.
By 2035, CERS could reach as high as $17.54, with a base case around $10.94 and support toward $7.40 — roughly +251% from $3.12. Buyers look set to stay in control over this stretch.
Expect CERS to range from $10.80 to $29.26 through 2040. The $17.13 average target implies a +449% move from current prices. That is up +57% on the projected 2035 average. Momentum favours further upside here.
The CERS price prediction for 2050 points to an average of $28.29 (low $15.80, high $52.98) — a potential gain of +807% on today's $3.12. Buyers look set to stay in control over this stretch.
Investing $1,000 in CERS today (≈ 320.512821 CERS) could be worth
$9,068.78
+$8,068.78 (+807%) by 2050 · US Dollar
Based on the average projected CERS price of $28.29 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CERSwould be worth at today's price.
$1,000 invested in CERS on Jul 10, 2025 (≈ 645.16131 CERS) would be worth
$2,012.9
+$1,012.9 (+101.3%) today · 2.01× · US Dollar
Based on a CERS entry price of $1.55 vs. today's $3.12.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.16 | $987.34 | -1.3% |
| 1 month ago | $2.56 | $1,218.75 | +21.9% |
| 3 months ago | $1.89 | $1,650.79 | +65.1% |
| 6 months ago | $2.27 | $1,374.45 | +37.4% |
| 1 year ago | $1.55 | $2,012.9 | +101.3% |
| All time (5.0y) ago | $5.15 | $605.83 | -39.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CERS forecast.
Our base-case forecast reaches $6.20 around 2030.
Implied market cap at $6.20: $1.24B
The multi-year forecast indicates bullish sentiment across the horizon with meaningful upside. In 2026 the average price is $3.16 with an ROI of 0 and a neutral sentiment, and by 2027 the average price rises to $4.40 with an ROI of 39.1. The forecast climbs to a 2030 average of $7.05 and a ROI of 123.1, then to 2040 with an average of $20.32 and a ROI of 543.1, and 2050 with an average of $33.53 and a ROI of 961.2, signaling substantial potential upside from current levels.
These projections assume ongoing demand for blood safety solutions and market expansion but carry inherent uncertainty and are not guarantees.
Tap a question to reveal the answer.
The forecast shows an average price of $7.05, with a min of $5.10 and a max of $10.55, and a bullish sentiment. The ROI is listed as 123.1.
The forecast indicates bullish sentiment from 2027 onward, with 2027 avg $4.40 (ROI 39.1%), 2028 avg $5.54 (ROI 75.3%), 2029 avg $6.17 (ROI 95.3%), 2030 avg $7.05 (ROI 123.1%), and 2050 avg $33.53 (ROI 961.2%). These are estimates and carry risk.
Yes. The 2027 forecast shows an average price of $4.40, with a 2027 min of $3.45. The 2026 max is $4.09, indicating a crossing above $4 in the near term.
Current price is $3.16 and market cap is $633.17M.
The 2040 forecast shows a min of $12.30, avg $20.32, max $35.86, with a ROI of 543.1 and a bullish sentiment.
Cerus Corporation Community Discussion
0Share your Cerus Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.